Key result
Resection plus adjuvant docetaxel and gemcitabine achieves symptom-free 9-month survival in right-heart metastatic ESS.
Why the study?
Intracardiac metastasis of endometrial stromal sarcoma is exceedingly rare and clinical experience is limited.
Case Report (n=1)
May support multimodality therapy in select right-heart metastases from ESS; hypothesis-generating and requires prospective validation.
The endometrial stromal sarcoma (EES) is a rare uterine malignancy and its intracardiac metastasis are exceedingly rare. We report a case of a 53-year-old female patient diagnosed with a metastatic tumor of a ESS in the right side of the heart, who underwent successful surgical resection and initiated chemotherapy with docetaxel and gemcitabine. At a 9-month follow-up, the patient was in New York Heart Association-Class I, without any further complications.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2021) conducted a case report in Metastatic endometrial stromal sarcoma in the right side of the heart (n=1). Surgical resection and chemotherapy (docetaxel and gemcitabine) was evaluated. Surgical resection followed by chemotherapy with docetaxel and gemcitabine resulted in NYHA Class I status without complications at 9 months in a woman with right heart metastatic ESS.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: